Although in vitro studies performed on HepG2 cells have shown that the transforming growth factor-beta (TGF-β) exerts an inhibitory effect on SeP secretion downregulating SeP promoter [22], in vivo evidences that describe a direct link between SeP and hepatic fibrosis in the setting of NAFLD are scarce. The gene discussed is SELENOP; the disease is metabolic dysfunction-associated steatotic liver disease.